Search

Catherine J Pachuk

from Jupiter, FL
Age ~67
Get Report
Also known as:
Catherine M Pachuk, Catherine P Pachuk, Catherine T Pachuk, Catherine J Tachuk, Cathy J Pachuk, Cathie J Pachuk, Catherine K, Catherine Packuk, Laura Cook
Phone and address:
1033 N Jeaga Dr, Jupiter, FL 33458
(215) 896-4403
Related to:
Walter Pachuk
Connected to:
Christopher R Pachunka, 46Jacob M Pachuta, 30Jimmy D Pachuta, 72Margery J Pachuta, 81Samantha J Pachyak, 45Brett Paci, 47Elisabetta L Paci, 92Viviana Paci, 63Ayn Pacia, 34Fields Pacia, 96

Catherine Pachuk Phones & Addresses

  • 1033 N Jeaga Dr, Jupiter, FL 33458 (215) 896-4403
  • 201 E Drinker St, Scranton, PA 18512
  • Dunmore, PA
  • Marlborough, MA
  • Palm Beach Gardens, FL
  • Northborough, MA
  • Blue Bell, PA
  • Lansdale, PA
  • Lackawaxen, PA
  • Lansdowne, PA
  • 1033 N Jeaga Dr, Jupiter, FL 33458

Work

Company: Pfizer Aug 2008 to Aug 2011 Position: Senior director oligonucleotide therapeutic unit, cambridge ma

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Pennsylvania 1981 to 1988 Specialities: Molecular Biology

Skills

Drug Discovery • Biotechnology • Pharmacology • Oncology • Clinical Development • Vaccines • Rnai • Virology • Clinical Trials • Drug Delivery • Sirna • Validation • Life Sciences • Nanotechnology • Chemistry • Cell Culture • Cro • Drug Development • In Vitro • Metabolic Syndrome • Hcv • Antiviral

Industries

Biotechnology

Resumes

Resumes

Catherine Pachuk Photo 1

Chief Scientific Officer And Business Unit Head

View page
Location:
115 south Apple St, Dunmore, PA 18512
Industry:
Biotechnology
Work:
Pfizer Aug 2008 - Aug 2011
Senior Director Oligonucleotide Therapeutic Unit, Cambridge Ma
Somahlution Aug 2008 - Aug 2011
Chief Scientific Officer and Business Unit Head
Nucleonics, Inc. 2000 - 2008
Vice President Preclinical Research
Pfizer Mar 1992 - Jun 2000
Assistant Research Fellow and Director
Gsk Jan 1989 - Mar 1992
Postdoc
Education:
University of Pennsylvania 1981 - 1988
Doctorates, Doctor of Philosophy, Molecular Biology
Skills:
Drug Discovery
Biotechnology
Pharmacology
Oncology
Clinical Development
Vaccines
Rnai
Virology
Clinical Trials
Drug Delivery
Sirna
Validation
Life Sciences
Nanotechnology
Chemistry
Cell Culture
Cro
Drug Development
In Vitro
Metabolic Syndrome
Hcv
Antiviral

Business Records

Name / Title
Company / Classification
Phones & Addresses
Catherine J. Pachuk
Owner
Kathy Karen Childrens Shoppe
Children's & Infants' Wear
201 E Drinker St, Dunmore, PA 18512
(570) 343-1383
Catherine Pachuk
Director, Secretary, Managing
Somahlution
Biotechnology · Home Health Care Services · Nonclassifiable Establishments · General Hospital
225 Chimney Cor Ln, Jupiter, FL 33458
3401 Fiechtner Dr S, Fargo, ND 58103
3369 39 St S, Fargo, ND 58104
(561) 766-2185
Catherine Pachuk
Director, Secretary
Crystal Cube Laboratories, Inc
Analytical Testing Lab Maintenance & Consulting Svcs · Nonclassifiable Establishments
4960 SW 52 St, Fort Lauderdale, FL 33314
1120 Holland Dr, Boca Raton, FL 33487
225 Chimney Cor Ln, Jupiter, FL 33458
3401 Fiechtner Dr S, Fargo, ND 58103

Publications

Us Patents

Conserved Hbv And Hcv Sequences Useful For Gene Silencing

View page
US Patent:
8350021, Jan 8, 2013
Filed:
Jun 10, 2004
Appl. No.:
10/560377
Inventors:
Catherine J. Pachuk - Cambridge MA, US
Chandrasekhar Satishchandran - Cambridge MA, US
Liat Mintz - Cambridge MA, US
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07H 21/04
US Classification:
536 245
Abstract:
Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.

In Vivo Delivery Of Double Stranded Rna To A Target Cell

View page
US Patent:
8524679, Sep 3, 2013
Filed:
Nov 6, 2007
Appl. No.:
12/514237
Inventors:
Catherine Pachuk - Northborough MA, US
Assignee:
Veritas Bio, LLC - Plymouth Meeting PA
International Classification:
C12N 15/11
A61K 48/00
C07H 21/02
C07H 21/04
US Classification:
514 44A, 536 245
Abstract:
The invention encompasses methods of delivering nucleic acids, including dsRNA, to mammalian target cells in vivo via intercellular transfer, wherein the dsRNA is delivered to or expressed in a first cell different from the target cell, wherein the first cell facilitates delivery of the dsRNA to the target cell.

Conserved Hbv And Hcv Sequences Useful For Gene Silencing

View page
US Patent:
8575327, Nov 5, 2013
Filed:
Dec 12, 2005
Appl. No.:
13/065601
Inventors:
Catherine J. Pachuk - Cambridge MA, US
Chandrasekhar Satishchandran - Cambridge MA, US
Vincent R. Zurawski - Cambridge MA, US
Liat Mintz - Cambridge MA, US
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C07H 21/02
C07H 21/04
C12Q 1/68
C12P 19/34
C12N 15/63
US Classification:
536 245, 435 6, 435 911, 435 9131, 435455, 536 231, 536 2431
Abstract:
Conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells, are provided. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.

Hepatitis C Dsrna Effector Molecules, Expression Constructs, Compositions, And Methods Of Use

View page
US Patent:
8614198, Dec 24, 2013
Filed:
Jun 23, 2008
Appl. No.:
12/666057
Inventors:
Daniel E. McCallus - Oaks PA, US
Catherine Pachuk - Northborough MA, US
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K 48/00
C12N 15/11
C07H 21/02
C07H 21/04
US Classification:
514 44A, 536 245
Abstract:
The present invention provides agents, compositions, constructs and methods for silencing HCV polynucleotides, as well as methods and compositions for treating or preventing HCV infection in a mammalian cell. In one aspect, the present invention provides an agent or composition comprising at least one double-stranded RNA effector molecule or complex. The double-stranded RNA effector molecule or complex comprises: (1) a sequence of at least 19 nucleotides having at least 90% identity with a nucleotide sequence within HCV Conserved Region 1 (SEQ ID NO: 2), HCV Conserved Region 2 (SEQ ID NO: 3), HCV Conserved Region 5 (SEQ ID NO: 4), (ATR)-1 (SEQ ID NO: 86), ATR-2 (SEQ ID NO: 87), ATR-3 (SEQ ID NO: 88), ATR-4 (SEQ ID NO: 89); and (2) its complementary sequence. In another aspect, the present invention provides a construct suitable for replication in a host cell, and/or suitable for expression of an RNA molecule or complex of the invention in vitro or in vivo. In a third aspect, the present invention provides a method for silencing HCV RNA in a mammalian cell, which comprises administering to the mammalian cell an agent, composition, or construct of the invention in a manner and amount effective to silence HCV RNA in the cell.

Targeting Opposite Strand Replication Intermediates Of Single-Stranded Viruses By Rnai

View page
US Patent:
20090137039, May 28, 2009
Filed:
Aug 29, 2008
Appl. No.:
12/201499
Inventors:
Daniel E. McCALLUS - , US
Catherine Pachuk - Northborough MA, US
Baohua Gu - Malvern PA, US
International Classification:
C12N 5/08
C12N 5/06
C12N 15/11
US Classification:
435366, 435375, 536 245
Abstract:
The invention relates to methods and compositions for modulating viral replication through double-stranded RNA-mediated gene silencing (RNAi), wherein the antiviral methods and compositions preferentially target opposite strand replication intermediates of single-stranded RNA viruses.

Multiple-Compartment Eukaryotic Expression Systems

View page
US Patent:
20090311788, Dec 17, 2009
Filed:
Oct 3, 2008
Appl. No.:
12/245431
Inventors:
Catherine PACHUK - Northborough MA, US
Chandrasekhar Satishchandran - Lansdale PA, US
International Classification:
C12N 15/67
C12N 5/10
C12N 15/63
US Classification:
435455, 435325, 4353201
Abstract:
Method and constructs for expressing heterologous sequences of interest in eukaryotic cells using multiple-compartment expression systems. These systems, which may be comprised of a single construct or multiple constructs, utilize at least two different promoters which are each active within a different subcellular compartment of the same eukaryotic cell. The system and constructs of the invention are particularly useful for achieving enhanced in vivo expression of RNA molecules capable of modulating the expression of target genes.

Methods And Compositions For Inhibiting The Function Of Polynucleotide Sequences

View page
US Patent:
20100172976, Jul 8, 2010
Filed:
Dec 18, 2009
Appl. No.:
12/642367
Inventors:
Chandrasekhar Satishchandran - Cambridge MA, US
Catherine J. Pachuk - Cambridge MA, US
Assignee:
ALNYLAM PHARMACEUTICALS, INC. - Cambridge MA
International Classification:
A61K 9/48
A61K 9/28
A61K 35/74
C12N 15/87
C12N 1/21
US Classification:
424463, 424474, 424 932, 435463, 4352523, 43525231, 43525232, 43525233, 43525234
Abstract:
A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein. The agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; or made in recombinant cultures of microorganisms and isolated therefrom, or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell. In methods of treatment of prophylaxis of virus infections, other pathogenic infections or certain cancers, these compositions are administered in amounts effective to reduce or inhibit the function of the target polynucleotide sequence, which can be of pathogenic origin or produced in response to a tumor or other cancer, among other sources.

Influenza Polynucleotides, Expression Constructs, Compositions, And Methods Of Use

View page
US Patent:
20100190842, Jul 29, 2010
Filed:
Apr 14, 2008
Appl. No.:
12/595412
Inventors:
Catherine J. Pachuk - Cambridge MA, US
Daniel E. McCallus - Cambridge MA, US
Assignee:
ALNYLAM PHARMACEUTICALS, INC. - Cambridge MA
International Classification:
A61K 31/7088
C07H 21/04
A61P 31/16
C12N 15/63
US Classification:
514 44 R, 536 231, 4353201
Abstract:
The invention provides isolated RNA molecules containing a stretch of nucleotides from a conserved Influenza sequence, and provides complementary RNA molecules thereto. The RNA molecules of the invention are also substantially non-homologous to human sequences. The RNA molecules of the invention include double-stranded RNAs comprising a first region that is a conserved Influenza sequence, and a second region that is at least substantially complementary to the first region. Such double-stranded RNAs include single short hairpin RNAs (shRNAs) as well as multi-target hairpin RNAs containing a plurality, or several, stem-loop structures. The present invention further provides expression constructs that provide for expression of one, or a plurality, of RNA molecules of the invention. The RNA molecules, expression constructs, and compositions of the present invention find use in reducing levels of Influenza A RNA, in reducing Influenza A virus titer, and in treating or preventing Influenza virus infection. The invention is effective against at least human, swine and avian originating strains of Influenza A, and makes gene-silencing therapeutic strategies for combating Influenza A infection feasible.
Control profile
Catherine J Pachuk from Jupiter, FL, age ~67 Get Report